[{"id":"58d26922-dd62-4243-8588-89fbcbf5d940","acronym":"","url":"https://clinicaltrials.gov/study/NCT02152995","created_at":"2021-03-24T14:59:26.184Z","updated_at":"2025-02-25T12:26:08.615Z","phase":"Phase 2","brief_title":"Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer","source_id_and_acronym":"NCT02152995","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • NRAS • HRAS • EGF","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61","tags":["HER-2 • KRAS • BRAF • NRAS • HRAS • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/14/2014","start_date":" 08/14/2014","primary_txt":" Primary completion: 08/25/2021","primary_completion_date":" 08/25/2021","study_txt":" Completion: 01/25/2026","study_completion_date":" 01/25/2026","last_update_posted":"2025-02-24"},{"id":"1ee7d622-cdd0-4c14-a5ad-ff67b7a251a6","acronym":"NCI-2021-11793","url":"https://clinicaltrials.gov/study/NCT05111561","created_at":"2021-11-08T14:53:11.471Z","updated_at":"2025-02-25T13:40:41.596Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","source_id_and_acronym":"NCT05111561 - NCI-2021-11793","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1","pipe":" | ","alterations":" BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion","tags":["HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • ZEN-3694"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 08/02/2022","start_date":" 08/02/2022","primary_txt":" Primary completion: 03/14/2025","primary_completion_date":" 03/14/2025","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-21"},{"id":"9746c38a-e183-480a-bcc4-ea83361a9977","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554328","created_at":"2022-09-26T14:56:09.383Z","updated_at":"2025-02-25T13:49:33.072Z","phase":"Phase 2","brief_title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554328","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation","tags":["KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Koselugo (selumetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-20"},{"id":"fb4d840f-ccf1-4e5e-ac00-2c10191c007e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554367","created_at":"2022-09-26T14:56:10.119Z","updated_at":"2025-02-25T13:54:43.263Z","phase":"Phase 2","brief_title":"Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554367","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • RAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12","tags":["KRAS • BRAF • NRAS • HRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Mektovi (binimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 08/26/2026","primary_completion_date":" 08/26/2026","study_txt":" Completion: 08/26/2026","study_completion_date":" 08/26/2026","last_update_posted":"2025-02-20"},{"id":"bb866355-1e34-4d35-9bb4-a41598c5e17e","acronym":"IMM1104-101","url":"https://clinicaltrials.gov/study/NCT05585320","created_at":"2022-10-18T14:57:21.622Z","updated_at":"2025-02-25T14:09:12.843Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05585320 - IMM1104-101","lead_sponsor":"Immuneering Corporation","biomarkers":" KRAS • HRAS • APC","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation","tags":["KRAS • HRAS • APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • atebimetinib (IMM-1-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 10/31/2022","start_date":" 10/31/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-19"},{"id":"12b710b2-1109-43fb-8b55-f68f0578591b","acronym":"FIT-001","url":"https://clinicaltrials.gov/study/NCT06026410","created_at":"2023-09-07T16:09:33.674Z","updated_at":"2025-02-25T14:18:15.893Z","phase":"Phase 1","brief_title":"KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors","source_id_and_acronym":"NCT06026410 - FIT-001","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • HRAS mutation","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Krazati (adagrasib) • darlifarnib (KO-2806)"],"overall_status":"Recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-02-12"},{"id":"1aa44e24-9704-4fe0-a608-34236855cfe0","acronym":"19-C-0017","url":"https://clinicaltrials.gov/study/NCT03745326","created_at":"2021-01-18T18:20:39.102Z","updated_at":"2024-07-02T16:34:38.005Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03745326 - 19-C-0017","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11","tags":["EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/16/2019","start_date":" 05/16/2019","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-05"},{"id":"92f8d52f-8230-4bcf-832a-25726a2e7d8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190941","created_at":"2021-01-18T15:44:01.911Z","updated_at":"2024-07-02T16:34:38.067Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03190941","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V","tags":["KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/21/2017","start_date":" 09/21/2017","primary_txt":" Primary completion: 06/29/2027","primary_completion_date":" 06/29/2027","study_txt":" Completion: 06/29/2028","study_completion_date":" 06/29/2028","last_update_posted":"2024-06-05"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"c588db17-efc8-49b9-af67-a28b72dc4313","acronym":"","url":"https://clinicaltrials.gov/study/NCT06096974","created_at":"2023-10-24T15:13:42.150Z","updated_at":"2024-07-02T16:35:31.995Z","phase":"Phase 1","brief_title":"Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS","source_id_and_acronym":"NCT06096974","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" PD-L1 • KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • HRAS mutation","tags":["PD-L1 • KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YL-17231"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-10-24"},{"id":"81882457-ba1a-48b0-8054-a1df3a396386","acronym":"TRAHD","url":"https://clinicaltrials.gov/study/NCT03714958","created_at":"2021-01-18T18:12:34.191Z","updated_at":"2025-02-25T15:43:15.903Z","phase":"Phase 1","brief_title":"Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type","source_id_and_acronym":"NCT03714958 - TRAHD","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • TP53 • NRAS • HRAS","pipe":" | ","alterations":" TP53 mutation • BRAF mutation • TP53 wild-type • HRAS mutation","tags":["KRAS • TP53 • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRAF mutation • TP53 wild-type • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • siremadlin (HDM201)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/20/2018","start_date":" 12/20/2018","primary_txt":" Primary completion: 09/12/2023","primary_completion_date":" 09/12/2023","study_txt":" Completion: 09/12/2023","study_completion_date":" 09/12/2023","last_update_posted":"2023-09-13"},{"id":"5cfcbe7d-4d03-4117-95be-9b8d7199f4ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04146298","created_at":"2021-01-18T20:14:11.889Z","updated_at":"2024-07-02T16:35:38.229Z","phase":"Phase 1/2","brief_title":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","source_id_and_acronym":"NCT04146298","lead_sponsor":"Changhai Hospital","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-09-01"},{"id":"2f6706b3-4373-4123-bd41-4a6388aa2fbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04566393","created_at":"2021-01-18T21:48:48.647Z","updated_at":"2024-07-02T16:35:39.652Z","phase":"","brief_title":"Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies","source_id_and_acronym":"NCT04566393","lead_sponsor":"xCures","biomarkers":" BRAF • NRAS • HRAS • MAPK1","pipe":" | ","alterations":" BRAF mutation • ER mutation • HRAS mutation","tags":["BRAF • NRAS • HRAS • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • ER mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-08-21"},{"id":"7de7e1ee-5af6-45a1-8fb5-cc69121b84de","acronym":"","url":"https://clinicaltrials.gov/study/NCT04487106","created_at":"2021-01-18T21:32:24.763Z","updated_at":"2024-07-02T16:35:53.866Z","phase":"Phase 2","brief_title":"Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT04487106","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • NRAS • KIT • HRAS • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • KIT mutation • NF1 mutation • HRAS mutation • CBL mutation","tags":["KRAS • BRAF • NRAS • KIT • HRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • KIT mutation • NF1 mutation • HRAS mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Mekinist (trametinib) • azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 02/09/2023","primary_completion_date":" 02/09/2023","study_txt":" Completion: 02/09/2023","study_completion_date":" 02/09/2023","last_update_posted":"2023-03-07"},{"id":"eedda5a0-ec8c-4127-bb15-acd6b4c60d96","acronym":"SEQ-HN","url":"https://clinicaltrials.gov/study/NCT03719690","created_at":"2021-01-18T18:13:51.350Z","updated_at":"2024-07-02T16:36:00.691Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy","source_id_and_acronym":"NCT03719690 - SEQ-HN","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" HRAS","pipe":" | ","alterations":" RAS wild-type • HRAS mutation • HRAS wild-type","tags":["HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • HRAS mutation • HRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 284","initiation":"Initiation: 11/05/2018","start_date":" 11/05/2018","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2022-11-09"},{"id":"71f1c969-b84a-461e-abff-6a5fd7a94ebc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02535650","created_at":"2021-01-17T17:10:25.985Z","updated_at":"2024-07-02T16:36:15.904Z","phase":"Phase 2","brief_title":"Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma","source_id_and_acronym":"NCT02535650","lead_sponsor":"Samsung Medical Center","biomarkers":" STK11 • HRAS","pipe":" | ","alterations":" STK11 mutation • HRAS mutation","tags":["STK11 • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 11/12/2015","start_date":" 11/12/2015","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2022-03-08"},{"id":"e5b2fa7d-d093-4b38-afac-9476bd5a7056","acronym":"MERAIODE","url":"https://clinicaltrials.gov/study/NCT03244956","created_at":"2021-01-18T16:02:03.431Z","updated_at":"2024-07-02T16:36:23.819Z","phase":"Phase 2","brief_title":"Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer","source_id_and_acronym":"NCT03244956 - MERAIODE","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • HRAS mutation • BRAF K601E • BRAF K601","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • HRAS mutation • BRAF K601E • BRAF K601"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 11/18/2021","primary_completion_date":" 11/18/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2021-09-28"},{"id":"05393640-65bf-4e1a-874e-2d7c1305fa9f","acronym":"KO-TIP-001","url":"https://clinicaltrials.gov/study/NCT02383927","created_at":"2021-01-17T17:10:25.340Z","updated_at":"2024-07-02T16:36:30.260Z","phase":"Phase 2","brief_title":"Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations","source_id_and_acronym":"NCT02383927 - KO-TIP-001","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" HRAS","pipe":" | ","alterations":" HRAS mutation","tags":["HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 11/30/2020","primary_completion_date":" 11/30/2020","study_txt":" Completion: 11/30/2020","study_completion_date":" 11/30/2020","last_update_posted":"2021-05-14"},{"id":"88762fb2-bc78-461a-9433-192ed0a1e084","acronym":"","url":"https://clinicaltrials.gov/study/NCT03415126","created_at":"2021-01-18T16:50:58.681Z","updated_at":"2024-07-02T16:36:43.443Z","phase":"Phase 1","brief_title":"A Study of ASN007 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03415126","lead_sponsor":"Asana BioSciences","biomarkers":" KRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • HRAS mutation","tags":["KRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERAS-007"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 01/19/2018","start_date":" 01/19/2018","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2020-07-09"},{"id":"b54409dc-6ce8-465c-838e-5c152a25bdbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03266159","created_at":"2021-03-26T09:18:25.614Z","updated_at":"2024-07-02T16:37:15.706Z","phase":"Phase 2","brief_title":"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors","source_id_and_acronym":"NCT03266159","lead_sponsor":"GlaxoSmithKline","biomarkers":" KRAS • NRAS • HRAS • NF1 • CCL2","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • NF1 mutation • HRAS mutation","tags":["KRAS • NRAS • HRAS • NF1 • CCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • NF1 mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • molibresib (GSK525762)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 08/19/2020","primary_completion_date":" 08/19/2020","study_txt":" Completion: 08/19/2020","study_completion_date":" 08/19/2020","last_update_posted":"2017-12-08"},{"id":"665677a6-0fc4-468c-9f91-7662da3caed6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01466257","created_at":"2021-01-18T06:06:13.378Z","updated_at":"2024-07-02T16:37:21.918Z","phase":"","brief_title":"Biomarkers in Patients With Head and Neck Cancer","source_id_and_acronym":"NCT01466257","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" PIK3CA • HRAS","pipe":" | ","alterations":" PIK3CA mutation • HRAS mutation","tags":["PIK3CA • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 11/21/2011","start_date":" 11/21/2011","primary_txt":" Primary completion: 01/01/2012","primary_completion_date":" 01/01/2012","study_txt":" Completion: 01/01/2012","study_completion_date":" 01/01/2012","last_update_posted":"2017-05-19"},{"id":"8b813b87-e417-4148-80ce-d8eeff56c1fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02573220","created_at":"2021-01-18T12:28:06.244Z","updated_at":"2024-07-02T16:37:27.148Z","phase":"Phase 1","brief_title":"Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer","source_id_and_acronym":"NCT02573220","lead_sponsor":"University of Chicago","biomarkers":" KRAS • NRAS • HRAS • UGT1A1","pipe":" | ","alterations":" KRAS mutation • RAS wild-type • HRAS mutation • UGT1A1*28 • UGT1A1*1*1","tags":["KRAS • NRAS • HRAS • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS wild-type • HRAS mutation • UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 08/01/2016","primary_completion_date":" 08/01/2016","study_txt":" Completion: 08/01/2016","study_completion_date":" 08/01/2016","last_update_posted":"2016-12-09"}]